Sanila Mughal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sanila Mughal has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Mohammed Mahmmoud Fadelallah Eljack
Faculty of Medicine and Health Sciences University of Bakhtalruda Ad Douiem Sudan
5 shared publications - Muhammad Hasanain
Dow Medical College, Karachi, Pakistan
3 shared publications - Amina Mahmud
Department of Medicine Dow University of Health Sciences Karachi Pakistan
2 shared publications Ayesha Sheikh
Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan
2 shared publications- Hamza Irfan
Department of Medicine Shaikh Khalifa Bin Zayed Al Nahyan Medical and Dental College Lahore Pakistan
2 shared publications - Hurais Malik
Department of Medicine, Fazaia Ruth Pfau Medical College, Karachi, Pakistan
2 shared publications
Latest Publications
- Open Access
- 31 May 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (6) , e72492
Reproxalap ‐ A Novel Treatment Option for Allergic Conjunctivitis – A Comprehensive Narrative Review
Background and Aims: Allergic conjunctivitis is a prevalent, immune‐mediated hypersensitivity disorder of the ocular surface affecting 10%–20% of the global population. Current therapeutic options, while effective to some extent, are often limited by side effects and inconsistent efficacy. Despite its widespread impact, allergic conjunctivitis receives comparatively less clinical attention than other chronic allergic conditions. This review aims to assess the therapeutic potential and clinical efficacy of Reproxalap, a novel ophthalmic solution targeting reactive aldehyde species (RASP), for the treatment of allergic conjunctivitis. Methods: A narrative review was conducted analyzing the pharmacological profile of Reproxalap and its clinical performance in phase 2 and phase 3 clinical trials. These trials evaluated the drug's safety, tolerability, and efficacy based on symptom relief, particularly ocular itching and inflammation. Results: Reproxalap demonstrated early‐onset and broad‐spectrum anti‐inflammatory activity through RASP inhibition. By trapping free aldehydes and modulating inflammatory mediators like cytokines and chemokines, it significantly reduced ocular inflammation. Clinical trial data indicated statistically significant improvement in itching scores and sustained symptom relief in patients with allergic conjunctivitis. The drug also showed a favorable safety profile, with minimal adverse events reported. Conclusion: Reproxalap represents a first‐in‐class RASP inhibitor with promising efficacy and safety for the treatment of allergic conjunctivitis. Its unique mechanism of action and encouraging clinical trial outcomes support its potential as a valuable therapeutic alternative that may improve patient outcomes and could also be applicable in other inflammatory ocular conditions.
- 31 May 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (6) , e72492
Open AccessReproxalap ‐ A Novel Treatment Option for Allergic Conjunctivitis – A Comprehensive Narrative Review
Background and Aims: Allergic conjunctivitis is a prevalent, immune‐mediated hypersensitivity disorder of the ocular surface affecting 10%–20% of the global population. Current therapeutic options, while effective to some extent, are often limited by side effects and inconsistent efficacy. Despite its widespread impact, allergic conjunctivitis receives comparatively less clinical attention than other chronic allergic conditions. This review aims to assess the therapeutic potential and clinical efficacy of Reproxalap, a novel ophthalmic solution targeting reactive aldehyde species (RASP), for the treatment of allergic conjunctivitis. Methods: A narrative review was conducted analyzing the pharmacological profile of Reproxalap and its clinical performance in phase 2 and phase 3 clinical trials. These trials evaluated the drug's safety, tolerability, and efficacy based on symptom relief, particularly ocular itching and inflammation. Results: Reproxalap demonstrated early‐onset and broad‐spectrum anti‐inflammatory activity through RASP inhibition. By trapping free aldehydes and modulating inflammatory mediators like cytokines and chemokines, it significantly reduced ocular inflammation. Clinical trial data indicated statistically significant improvement in itching scores and sustained symptom relief in patients with allergic conjunctivitis. The drug also showed a favorable safety profile, with minimal adverse events reported. Conclusion: Reproxalap represents a first‐in‐class RASP inhibitor with promising efficacy and safety for the treatment of allergic conjunctivitis. Its unique mechanism of action and encouraging clinical trial outcomes support its potential as a valuable therapeutic alternative that may improve patient outcomes and could also be applicable in other inflammatory ocular conditions.
- 23 July 2025
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 37 (10) , e70070
Exploring the link between dopamine dysregulation and eating disorders: A narrative review
The prevalence of eating disorders (ED), such as anorexia, bulimia, and binge‐eating disorders, is on the rise, and it is imperative to explore the pathophysiological aspects and associations of these disorders to provide better and precise treatment. Dopamine is an essential hormone and a neurotransmitter involved in an array of processes and pathways. Disruption of any of the dopamine pathways can lead to diseases such as Parkinson's, Huntington's, schizophrenia, or anhedonia. The mesolimbic pathway of dopamine has a special association with the feeding behavior of a person, and disruption of this pathway has been shown to be associated with ED. In this article, we comprehensively assess the relation between dopamine and ED and discuss the clinical implications involving the pharmacological associations of drugs influencing dopamine levels and their impact on the treatment of ED.
- 23 July 2025
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 37 (10) , e70070
Exploring the link between dopamine dysregulation and eating disorders: A narrative review
The prevalence of eating disorders (ED), such as anorexia, bulimia, and binge‐eating disorders, is on the rise, and it is imperative to explore the pathophysiological aspects and associations of these disorders to provide better and precise treatment. Dopamine is an essential hormone and a neurotransmitter involved in an array of processes and pathways. Disruption of any of the dopamine pathways can lead to diseases such as Parkinson's, Huntington's, schizophrenia, or anhedonia. The mesolimbic pathway of dopamine has a special association with the feeding behavior of a person, and disruption of this pathway has been shown to be associated with ED. In this article, we comprehensively assess the relation between dopamine and ED and discuss the clinical implications involving the pharmacological associations of drugs influencing dopamine levels and their impact on the treatment of ED.
- Open Access
- 13 June 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (8) , 5335-5337
Reducing the burden of surgical site infections in low and middle-income countries: challenges and recommendations
Surgical site infections (SSIs) are a significant and growing challenge in surgical care, particularly in low- and middle-income countries (LMICs), where limited resources and inadequate infection control amplify their impact. Affecting up to 25% of surgical patients in some regions, SSIs lead to prolonged hospital stays, increased healthcare costs, and substantial patient suffering. Multidrug-resistant pathogens and inadequate adherence to global guidelines exacerbate the issue, highlighting the need for tailored interventions. Innovative approaches, such as active surveillance programs, routine changes in surgical practices, and enhanced patient education, have shown promise in reducing SSI rates. By prioritizing infection prevention strategies, resource optimization, and collaborative efforts between healthcare providers and policymakers, LMICs can significantly improve surgical outcomes and reduce the burden of SSIs.
- 13 June 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (8) , 5335-5337
Open AccessReducing the burden of surgical site infections in low and middle-income countries: challenges and recommendations
Surgical site infections (SSIs) are a significant and growing challenge in surgical care, particularly in low- and middle-income countries (LMICs), where limited resources and inadequate infection control amplify their impact. Affecting up to 25% of surgical patients in some regions, SSIs lead to prolonged hospital stays, increased healthcare costs, and substantial patient suffering. Multidrug-resistant pathogens and inadequate adherence to global guidelines exacerbate the issue, highlighting the need for tailored interventions. Innovative approaches, such as active surveillance programs, routine changes in surgical practices, and enhanced patient education, have shown promise in reducing SSI rates. By prioritizing infection prevention strategies, resource optimization, and collaborative efforts between healthcare providers and policymakers, LMICs can significantly improve surgical outcomes and reduce the burden of SSIs.
- Open Access
- 5 June 2025
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 13, 1469486
The contemporary spell of heat stroke in Karachi amid global warming and power crisis: a threatened call for medical emergency
The study examines the impact of population density, air pollution, and temperature on heat stroke cases in Karachi, focusing on stroke-related mortality from 2010 to 2024. It develops an intelligent system for adaptive forecasting, incorporating population increase, air quality, meteorological activity, and mortality data, presenting urban vulnerability to health crises. A Pearson correlation analysis was used to determine the association between these factors, which makes it possible to present urban vulnerability to health crises from various angles that are systematically relevant and interdependent at the same time. This study is unique because it takes an integrated approach, relating urban stressors and climate conditions to public health outcomes in Karachi, a context that has been neglected in previous studies.
- 5 June 2025
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 13, 1469486
Open AccessThe contemporary spell of heat stroke in Karachi amid global warming and power crisis: a threatened call for medical emergency
The study examines the impact of population density, air pollution, and temperature on heat stroke cases in Karachi, focusing on stroke-related mortality from 2010 to 2024. It develops an intelligent system for adaptive forecasting, incorporating population increase, air quality, meteorological activity, and mortality data, presenting urban vulnerability to health crises. A Pearson correlation analysis was used to determine the association between these factors, which makes it possible to present urban vulnerability to health crises from various angles that are systematically relevant and interdependent at the same time. This study is unique because it takes an integrated approach, relating urban stressors and climate conditions to public health outcomes in Karachi, a context that has been neglected in previous studies.
- Open Access
- 28 February 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (3) , 1117-1119
A new chapter in CML treatment: the promise of asciminib
Asciminib, a groundbreaking treatment for chronic myeloid leukemia (CML), has gained FDA approval as the first STAMP inhibitor. Targeting the myristoyl pocket of the BCR-ABL1 protein, this drug offers a unique mechanism to overcome resistance to traditional tyrosine kinase inhibitors (TKIs). Clinical trials, such as the ASC4FIRST study, demonstrate asciminib’s superior efficacy compared to existing TKIs, achieving higher molecular response rates and fewer severe side effects. Its favorable safety profile, characterized by reduced vascular and pulmonary risks, supports improved patient adherence and long-term outcomes. While asciminib shows promise as a second-line or even frontline therapy, long-term data on its durability, adverse effects, and potential drug interactions are still evolving. Current research highlights its potential use in pediatric cases and in combination therapies for other leukemia types. Asciminib represents a significant advancement in CML treatment, paving the way for more targeted and tolerable cancer therapies.
- 28 February 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (3) , 1117-1119
Open AccessA new chapter in CML treatment: the promise of asciminib
Asciminib, a groundbreaking treatment for chronic myeloid leukemia (CML), has gained FDA approval as the first STAMP inhibitor. Targeting the myristoyl pocket of the BCR-ABL1 protein, this drug offers a unique mechanism to overcome resistance to traditional tyrosine kinase inhibitors (TKIs). Clinical trials, such as the ASC4FIRST study, demonstrate asciminib’s superior efficacy compared to existing TKIs, achieving higher molecular response rates and fewer severe side effects. Its favorable safety profile, characterized by reduced vascular and pulmonary risks, supports improved patient adherence and long-term outcomes. While asciminib shows promise as a second-line or even frontline therapy, long-term data on its durability, adverse effects, and potential drug interactions are still evolving. Current research highlights its potential use in pediatric cases and in combination therapies for other leukemia types. Asciminib represents a significant advancement in CML treatment, paving the way for more targeted and tolerable cancer therapies.
- Open Access
- 6 December 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (49) , e40735
Emerging paradigm: Molecularly targeted therapy with Dabrafenib and Trametinib in recurring pediatric gliomas with BRAF mutations: A narrative review
Gliomas are tumors arising in the central nervous system, frequently associated with Class I mutations and BRAF fusions. These mutations are adverse prognostic factors in juvenile gliomas, leading to high rates of recurrence and poor response to current treatments. The blood-brain barrier and the heterogeneity of gliomas complicate the development of a single treatment strategy for all cases. This review aims to evaluate the efficacy and safety of combination therapies, particularly Dabrafenib and Trametinib, in pediatric gliomas with BRAF V600 mutations and discusses their potential in improving clinical outcomes. A review of recent clinical trials was conducted to assess the impact of targeted therapies, especially the combination of Dabrafenib and Trametinib, on glioma treatment outcomes. Additional therapies are also explored. Combination therapy with Dabrafenib, a BRAF kinase inhibitor, and Trametinib, a MEK inhibitor, has shown significant improvement in overall survival and progression-free survival for pediatric patients with BRAF V600-mutant gliomas. Recent clinical data from 2023 demonstrated enhanced tumor control, reduced relapse rates, and improved safety profiles compared to conventional therapies. Dabrafenib and Trametinib offer a promising targeted therapy for juvenile gliomas with BRAF V600 mutations, with better survival outcomes and manageable safety profiles. However, challenges remain in managing side effects such as fever, headache, lethargy, and rash. Further research into resistance mechanisms and long-term effects is necessary to optimize treatment strategies. Other therapies, such as everolimus and Selumetinib, also show potential and warrant further investigation.
- 6 December 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (49) , e40735
Open AccessEmerging paradigm: Molecularly targeted therapy with Dabrafenib and Trametinib in recurring pediatric gliomas with BRAF mutations: A narrative review
Gliomas are tumors arising in the central nervous system, frequently associated with Class I mutations and BRAF fusions. These mutations are adverse prognostic factors in juvenile gliomas, leading to high rates of recurrence and poor response to current treatments. The blood-brain barrier and the heterogeneity of gliomas complicate the development of a single treatment strategy for all cases. This review aims to evaluate the efficacy and safety of combination therapies, particularly Dabrafenib and Trametinib, in pediatric gliomas with BRAF V600 mutations and discusses their potential in improving clinical outcomes. A review of recent clinical trials was conducted to assess the impact of targeted therapies, especially the combination of Dabrafenib and Trametinib, on glioma treatment outcomes. Additional therapies are also explored. Combination therapy with Dabrafenib, a BRAF kinase inhibitor, and Trametinib, a MEK inhibitor, has shown significant improvement in overall survival and progression-free survival for pediatric patients with BRAF V600-mutant gliomas. Recent clinical data from 2023 demonstrated enhanced tumor control, reduced relapse rates, and improved safety profiles compared to conventional therapies. Dabrafenib and Trametinib offer a promising targeted therapy for juvenile gliomas with BRAF V600 mutations, with better survival outcomes and manageable safety profiles. However, challenges remain in managing side effects such as fever, headache, lethargy, and rash. Further research into resistance mechanisms and long-term effects is necessary to optimize treatment strategies. Other therapies, such as everolimus and Selumetinib, also show potential and warrant further investigation.
- Open Access
- 21 July 2024
- Published by Wiley in Clinical Case Reports
- Vol. 12 (7) , e9184
Rupture of sinus of Valsalva in a young laborer: A rare case report
Key Clinical Message: Ruptured sinus of Valsalva (RSOV) upon physical exertion is rare but should be considered in differential in young adults. Symptoms of acute heart failure, hemodynamic instability, and continuous heart murmur raises suspicion for RSOV and requires emergent surgical repair of right ventricular outflow tract.
- 21 July 2024
- Published by Wiley in Clinical Case Reports
- Vol. 12 (7) , e9184
Open AccessRupture of sinus of Valsalva in a young laborer: A rare case report
Key Clinical Message: Ruptured sinus of Valsalva (RSOV) upon physical exertion is rare but should be considered in differential in young adults. Symptoms of acute heart failure, hemodynamic instability, and continuous heart murmur raises suspicion for RSOV and requires emergent surgical repair of right ventricular outflow tract.
- Open Access
- 1 July 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (8) , 4664-4667
Precision medicine in peripartum cardiomyopathy: advancing diagnosis and management through genomic and phenotypic integration
Peripartum cardiomyopathy (PPCM) is a rare and life-threatening cardiac condition characterized by heart failure due to left ventricular systolic dysfunction, often developing in late pregnancy or the early postpartum period. Despite being a leading cause of maternal morbidity and mortality, clinical presentation of PPCM frequently overlaps with normal pregnancy-related physiological changes, causing diagnostic delays and increased complications. Current management strategies, primarily derived from general heart failure protocols, are evolving to address the unique aspects of PPCM. This includes the development of personalized medicine approaches that integrate genetic profiling, biomarker evaluation, and clinical phenotyping. Notable genes such as titin (TTN), Bcl2-associated athanogene 3 (BAG3), and lamin A/C (LMNA) are implicated in PPCM, revealing a complex genetic landscape similar to other cardiomyopathies. Biomarkers like N-terminal pro-brain-type natriuretic peptide (NT-proBNP) and cardiac troponin T (cTnT) are under investigation for their diagnostic and prognostic value, indicating that personalized treatments hold the promise of enhancing diagnostic precision and therapeutic outcomes by tailoring interventions to individual patient profiles. This review article aims to highlight how integrating genetic and phenotypic data can establish a novel framework for managing PPCM, potentially transforming treatment paradigms and improving long-term outcomes.
- 1 July 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (8) , 4664-4667
Open AccessPrecision medicine in peripartum cardiomyopathy: advancing diagnosis and management through genomic and phenotypic integration
Peripartum cardiomyopathy (PPCM) is a rare and life-threatening cardiac condition characterized by heart failure due to left ventricular systolic dysfunction, often developing in late pregnancy or the early postpartum period. Despite being a leading cause of maternal morbidity and mortality, clinical presentation of PPCM frequently overlaps with normal pregnancy-related physiological changes, causing diagnostic delays and increased complications. Current management strategies, primarily derived from general heart failure protocols, are evolving to address the unique aspects of PPCM. This includes the development of personalized medicine approaches that integrate genetic profiling, biomarker evaluation, and clinical phenotyping. Notable genes such as titin (TTN), Bcl2-associated athanogene 3 (BAG3), and lamin A/C (LMNA) are implicated in PPCM, revealing a complex genetic landscape similar to other cardiomyopathies. Biomarkers like N-terminal pro-brain-type natriuretic peptide (NT-proBNP) and cardiac troponin T (cTnT) are under investigation for their diagnostic and prognostic value, indicating that personalized treatments hold the promise of enhancing diagnostic precision and therapeutic outcomes by tailoring interventions to individual patient profiles. This review article aims to highlight how integrating genetic and phenotypic data can establish a novel framework for managing PPCM, potentially transforming treatment paradigms and improving long-term outcomes.
- Open Access
- 4 June 2024
- Published by Wiley in Health Science Reports
- Vol. 7 (6) , e2150
AI‐driven drug discovery: Exploring Abaucin as a promising treatment against multidrug‐resistant Acinetobacter baumannii
Background and Aims: This study presents a comprehensive overview of a well‐recognized critical pathogen Acinetobacter baumannii and demonstrates the potential of artificial intelligence (AI) in discovering new antibiotics. It is well‐known for causing serious infections, especially in patients admitted to intensive care units, which is further compromised by bacterium's resistance to even last‐resort antibiotics like carbapenems, posing critical challenges in its treatment and eradication. This article discusses Abaucin, a revolutionary antibiotic created from artificial intelligence, as a creative and potential treatment for A. baumannii.Methods: A comprehensive literature search was conducted using various databases including PubMed, Google Scholar, Cochrane, Science Direct, MEDLINE. Only articles written in English were considered. This correspondence was written after a thorough evaluation of all the articles that discussed Abaucin's discovery, potency against A. baumannii, and the potential of AI in discovering new antibiotics. In addition, references from the selected articles were also examined to ensure a comprehensive review of the literature.Results: This article highlights the discovery of a novel AI‐derived antibiotic, Abaucin that offers a promising solution for A. baumannii infections. Abaucin has a narrow range of action that minimizes the risk of inter‐pathogen spread of resistance, making the drug more appealing and effective. Its potential to suppress wound infections caused by multidrug‐resistant A. baumannii paves a hope for the eradication of superbugs. Further investigation and trials are needed to determine its effectiveness in human subjects and its integrity in the clinical workflow. machine learning (ML) and precision approach could revolutionize treatment strategies.Conclusion: The discovery of Abaucin as an antibiotic to combat drug‐resistant A. baumannii bacteria showcases AI and ML's potential to uncover novel antibiotics, thereby offering alternative treatment options. This novel inception of the AI‐derived antibiotic, Abaucin marks the first step in introducing an innovative treatment option and represents a substantial leap in the treatment of drug‐resistant illnesses and the use of AI in medical advancements.
- 4 June 2024
- Published by Wiley in Health Science Reports
- Vol. 7 (6) , e2150
Open AccessAI‐driven drug discovery: Exploring Abaucin as a promising treatment against multidrug‐resistant Acinetobacter baumannii
Background and Aims: This study presents a comprehensive overview of a well‐recognized critical pathogen Acinetobacter baumannii and demonstrates the potential of artificial intelligence (AI) in discovering new antibiotics. It is well‐known for causing serious infections, especially in patients admitted to intensive care units, which is further compromised by bacterium's resistance to even last‐resort antibiotics like carbapenems, posing critical challenges in its treatment and eradication. This article discusses Abaucin, a revolutionary antibiotic created from artificial intelligence, as a creative and potential treatment for A. baumannii.Methods: A comprehensive literature search was conducted using various databases including PubMed, Google Scholar, Cochrane, Science Direct, MEDLINE. Only articles written in English were considered. This correspondence was written after a thorough evaluation of all the articles that discussed Abaucin's discovery, potency against A. baumannii, and the potential of AI in discovering new antibiotics. In addition, references from the selected articles were also examined to ensure a comprehensive review of the literature.Results: This article highlights the discovery of a novel AI‐derived antibiotic, Abaucin that offers a promising solution for A. baumannii infections. Abaucin has a narrow range of action that minimizes the risk of inter‐pathogen spread of resistance, making the drug more appealing and effective. Its potential to suppress wound infections caused by multidrug‐resistant A. baumannii paves a hope for the eradication of superbugs. Further investigation and trials are needed to determine its effectiveness in human subjects and its integrity in the clinical workflow. machine learning (ML) and precision approach could revolutionize treatment strategies.Conclusion: The discovery of Abaucin as an antibiotic to combat drug‐resistant A. baumannii bacteria showcases AI and ML's potential to uncover novel antibiotics, thereby offering alternative treatment options. This novel inception of the AI‐derived antibiotic, Abaucin marks the first step in introducing an innovative treatment option and represents a substantial leap in the treatment of drug‐resistant illnesses and the use of AI in medical advancements.